MariMed Inc.

MariMed Inc. lands at 48 on the CIN composite, a Neutral outcome with conviction of 1/5. Fundamentals carry 35 percent of the model, regulatory posture 25, market signal 25, and editorial density 15, with every pillar contribution auditable. Fundamentals leads the pillar table at 60, and is the main lever behind the Neutral conclusion. The offset comes from editorial at 30, which pulls the composite toward the middle of the band.

The observable inputs tell a straightforward story: reported revenue growth of 4.2 percent year over year, an operating margin of 0.8 percent, gross margin of 36.0 percent, a market cap near 27 million. Every figure is auditable in the accompanying pillar table. All inputs are drawn from primary regulatory filings, licensed fundamentals data, institutional pricing feeds, and CIN newsroom coverage density. Because every ticker in the CIN universe is scored on the same 336-name basis, MariMed Inc. slots into a direct comparison rather than a bespoke narrative, and the score refreshes on the primary-source ingest cadence.

The forward path is set by fundamentals, which carry 60 of this rating. A quarterly print showing revenue above the trailing four-quarter run rate — paired with a defensible operating margin — would justify a tighter band; the reverse would loosen it.